Skip to main content

Trying to Quit His Day Job


Even after he signed on as president and COO of Hyseq, Ted Love found himself shuttling between jobs, spending mornings as senior vice president of development at Advanced Medicine and afternoons at Hyseq. What drove him to those lengths? “Obviously, George is a legend,” he says, referring to the Hyseq CEO who hired him. “The chance to work side by side with George Rathmann is a hard thing to walk away from.”

With his background in the development of biopharmaceutical products, Hyseq hopes that Love will be its ticket for the discovery train. He says his objective is to turn Hyseq into a company that uses its bioinformatics information to make drugs.

The organizational steps of getting a drug to market shouldn’t be a problem for Love — in his previous roles at Advanced Medicine and Genentech, he’s been there, done that. But it’s going to take more than experience. “We’re going to have to attract more money,” he says. “It takes a lot of money to take a drug from preclinical studies to approval.”

— Meredith Salisbury


The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.